PDGFR and KDR Inhibitors for Liver Fibrosis

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43DK085771-01
Agency Tracking Number: DK085771
Amount: $269,786.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: NIDDK
Solicitation Number: PHS2010-2
Small Business Information
DUNS: 053129065
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (516) 562-1140
Business Contact
Phone: (516) 326-1200
Email: igoldberg@angion.com
Research Institution
DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to triple over the next decade as a result of the hepatitis C epidemic and the growing incidence of liver disease associated with non-alcoholic steatohepatitis. Currently available therapies, including antivirals, are largely ineffective in treating the underlying fibrosis, and in the majority of cases, liver transplantation is the only effective cure. Liver fibrosis, irrespective of its etiology, reflects common cellular and molecular pathophysiology. Activation of hepatic stellate cells and conversion to myofibroblasts is the dominant event in fibrogenesis, and proceeds along a continuum that involves progressive changes in cellular function. Signaling through the platelet-derived growth factor (PDGF) pathway and vascular endothelial growth factor (VEGF) pathway play important roles in liver fibrosis. Angion has identified a small molecule, ANG-3154, that inhibits activation of the PDGF receptor (PDGFR-b) and the (KDR) and their tyrosine kinase activities. Preliminary data also indicate that this compound is antifibrotic in vivo. Our long-term goal is the development of small molecule dual inhibitors of PDGFR-b and KDR as potential therapeutics for fibrotic liver disease as well as fibrotic disease in other organs. The objective of this application is to identify such inhibitors and evaluate them in two clinically relevant animal models of liver fibrosis. PUBLIC HEALTH RELEVANCE: Small molecule dual inhibitors of the PDGFR and KDR receptors are potential therapeutics for fibrotic disease in the liver, as well as other major organs.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government